Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: A critique

Journal of Rheumatology

Volumn 23, Issue SUPPL. 46, 1996, Pages 44-59

  Shapiro, Samuel ^a,b,c  

^a BOSTON UNIVERSITY   (United States)

^b Department of Epidemiology ^*  (United States)

^c Showa Denko Materials Co   (Japan)

Author keywords

diagnosis; eosinophilia myalgia syndrome; epidemiology; L tryptophan

Indexed keywords

TRYPTOPHAN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; PRIORITY JOURNAL; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG CONTAMINATION; EOSINOPHILIA; EPIDEMIOLOGY; FASCIITIS;

CASE-CONTROL STUDIES; DRUG CONTAMINATION; EOSINOPHILIA; EOSINOPHILIA-MYALGIA SYNDROME; EPIDEMIOLOGIC METHODS; FASCIITIS; HUMANS; TRYPTOPHAN;

EID: 0030255889     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Hertzman PA, Blevins WL, Mayer J, et al: Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990;322:869-73.
2. Eidson M, Philen RM, Sewell CM, Voorhees R, Kilbourne EM: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;335:645-8.
3. Eosinophilia-myalgia syndrome - New Mexico. MMWR Morb Mortal Wkly Rep 1989;38:765-7.
4. Swygert LA, Maes EF, Sewell LE, et al: Eosinophilia-myalgia syndrome. Results of national surveillance. JAMA 1990;264:1698-703.
5. New Mexico Health and Environment Department. Press release. November 13, 1989.
6. Nightingale S: From the Food and Drug Administration: Update on EMS and L-tryptophan. JAMA 1992;268:1828.
7. Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon and New York, 1989. MMWR Morb Mortal Wkly Rep 1989;38:785-8.
8. Hibbs JR, Mittleman B, Hill P, Medsger TA: L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak. Arthritis Rheum 1992;35:299-303.
9. Slutsker L, Hoesly FC, Miller L, et al: Eosinophilia-myalgia syndrome associated with exposure to L-tryptophan from a single manufacturer. JAMA 1990;322:874-81.
10. Belongia EA, Hedberg C, Gleich GJ, et al: An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357-65.
11. Kamb ML, Murphy JJ, Jones JL, et al: Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992;267:77-82.
12. Henning KJ, Jean-Baptiste E, Singh T, Hill RH, Friedman SM: Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan. J Rheumatol 1993;20:273-8.
13. Back EE, Henning KJ, Kallenbach LR, et al: Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York. J Rheumatol 1993;20:666-72.
14. Kilbourne EM: Eosinophilia-myalgia syndrome: Coming to grips with a new illness. Epidemiol Rev 1992;14:16-36.
15. Horwitz RI, Daniels SR: Bias or biology: Evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome. J Rheumatol 1996;(suppl 46)23:60-72.
16. Shapiro S: L-tryptophan and eosinophilia-myalgia syndrome (letter). Lancet 1994;343:1035-6.
17. Shapiro S: L-tryptophan and eosinophilia-myalgia syndrome (letter). Lancet 1994;344:817-8.
18. Eidson M, Philen RM, Sewell CM, Voorhees RE, Kilbourne EM: L-tryptophan and eosinophilia-myalgia syndrome (reply to letter). Lancet 1994;343:1036-7.
19. Kilbourne EM, Eidson M, Philen RM, Vorhees RE, Sewell CM: L-tryptophan and eosinophilia-myalgia syndrome (reply to letter). Lancet 1994;344:818-9.
20. Rothman KJ: Modern Epidemiology. Boston: Little, Brown, 1986.
21. Shumacher ER: A scleroderma-like syndrome with fasciitis, myositis and eosinophilia. Ann Intern Med 1976;84:49-50.
22. Barnes L, Rodnan GP, Medsger TA, Short D: Eosinophilic fasciitis: A pathologic study of 20 cases. Am J Pathol 1979;96:493-518.
23. Bjelle A, Henrikkson KG, Hofer PA: Polymyositis in eosinophilic fasciitis: Review and case report. Eur Neurol 1980;19:128-37.
24. Coyle HE, Chapman RS: Eosinophilic fasciitis (Schulman syndrome) in association with morphea and systemic sclerosis. Acta Derm Venereol (Stockh) 1980;60:181-2.
25. Mahmoud AA, Austen KF, eds: The Eosinophil in Health and Disease. New York: Grune and Stratton, 1980.
26. Chan MK, Lages W: Eosinophilic fasciitis: Visceral involvement. Arch Intern Med 1982;142:2201-2.
27. Fauci AS, Harley JB, Roberts WC, et al: NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic and therapeutic considerations. Ann Intern Med 1982;97:78-92.
28. World Health Organization: Toxic oil syndrome. Mass food poisoning in Spain. Report on a WHO meeting. Madrid, March 21-25, 1983. Copenhagen: WHO, 1983.
29. Drosos AA, Papandimitrou CS, Moutsopoulos HM: An overlap of diffuse fasciitis with eosinophilia and scleroderma. Rheumatol Int 1984;4:187-9.
30. Lanham JG, Elkon KB, Pusey CD, Hughes GR: Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
31. Jacobs MB: Eosinophilic fasciitis, reactive hepatitis and splenomegaly. Arch Intern Med 1985;145:162-3.
32. Falanga V, Malsgor TA: Frequency, levels, and significance of blood eosinophilia in systemic sclerosis. J Am Acad Dermatol 1987;17:648-56.
33. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JH, Moore SB: Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988;17:221-31.
34. Kaufman LD, Kephart GM, Seidman RJ, et al: The spectrum of eosinophilic myositis. Clinical and immunopathogenic studies of 3 patients, and review of the literature. Arthritis Rheum 1993;36:1014-24.
35. Varga J, Griffin R, Newman JH, Jiminez SA: Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 1991;18:259-63.
36. Slone D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD: Drug evaluation after marketing: A policy perspective. Ann Intern Med 1979;90:257-61.
37. Philen RM, Eidson EM, Kilbourne EM, et al: Eosinophilia myalgia syndrome: A clinical case series of 21 patients. Arch Intern Med 1991;151:533-7.
38. Stieber T: Puzzling syndrome strikes 4 more. Albuquerque Journal. November 9, 1989.
39. Wagner K, Elmore J, Horwitz R: Diagnostic bias and the eosinophilia-myalgia syndrome (abstr). J Gen Intern Med 1994;(suppl 2)9:37.
40. Hudson JI, Pope HG, Daniels SR, Horwitz RI: Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia? JAMA 1993;269:3108-9.
41. Swanson M, Cook R: Drugs, Chemicals and Blood Dyscrasias. Hamilton, IL: Drug Intelligence Publications, 1977.
42. Davies DM, ed: Textbook of Adverse Drug Reactions. 4th ed. Oxford: Oxford University Press, 1991.
43. Doll R: The aetiology of the Spanish toxic oil syndrome: Interpretation of the epidemiological evidence, 1987. World Health Organization, 1987.
44. WHO Anniversary Symposium. Adverse drug reactions. A global perspective on signal generation and analysis. A symposium arranged by WHO Collaborating Centre for International Drug Monitoring. National Board of Health and Welfare, and University of Uppsala, Sweden, September 22-23, 1988. Uppsala, Sweden: Proceedings.
45. Sun RKP, Ginsberg CA, Taylor JP, et al: A population-based study of amino-acid-associated eosinophilia in Travis County, Texas, 1989. Am J Public Health; [in press].
46. Brigden ML, Herak MG: Incidence and clinical significance of unsuspected eosinophilia discovered by automated WBC differential counting. Lab Med 1993;24:173-6.
47. Case records of the Massachusetts General Hospital Case 4 - 1990. N Engl J Med 1990;322:252-61.
48. Gorn A: Case 4 - 1990; eosinophilic fasciitis. N Engl J Med 1990;322:931.